insights_auto
Why is MVIR up 5,77%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEK 1,69
arrow_upward
+5,77%(+0,092) 1D
2 ຕ.ລ., 17 ໂມງ 29 ນາທີ 51 ວິນາທີ GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK 1,71
High
SEK 1,78
Low
SEK 1,67
Mkt. cap
1,06 ຕື້
Avg. vol.
1,88 ລ້ານ
Volume
2,72 ລ້ານ
52-wk high
SEK 2,88
52-wk low
SEK 0,34
EPS
SEK-0,37
Shares outstanding
624,18 ລ້ານ
No. of employees
6
Open
SEK 1,71
High
SEK 1,78
Low
SEK 1,67
Mkt. cap
1,06 ຕື້
Avg. vol.
1,88 ລ້ານ
Volume
2,72 ລ້ານ
52-wk high
SEK 2,88
52-wk low
SEK 0,34
EPS
SEK-0,37
Shares outstanding
624,18 ລ້ານ
No. of employees
6
News stories
From web sources and news partners
www.marketscreener.com
·
15 ຊົ່ວໂມງກ່ອນ
DNB Carnegie resumes commissioned coverage of Medivir, sees strengthened portfolio and financing
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB